Pharmaceutical

BMS and 2seventy bio’s Abecma gains approval for multiple myeloma

Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma have received FDA approval for relapsed or refractory multiple myeloma (RRMM).

Apr 9, 2024 - 00:00
BMS and 2seventy bio’s Abecma gains approval for multiple myeloma
Bristol Myers Squibb (BMS) and 2seventy bio’s Abecma have received FDA approval for relapsed or refractory multiple myeloma (RRMM).
Read the original article

Tags:

Previous Article

Medicxi and Starpharma to develop dendrimer-based cancer treatments

Next Article

FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for solid tumours

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Selecta Biosciences files patent for enhanced gene ther...

Mar 13, 2024

WHO recommends second malaria vaccine, hoping to address supply issues

WHO recommends second malaria vaccine, hoping to addres...

Oct 2, 2023

Patient comfort in AI-driven healthcare linked to familiarity with technology

Patient comfort in AI-driven healthcare linked to famil...

Oct 13, 2023